<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02890147</url>
  </required_header>
  <id_info>
    <org_study_id>PRECISESADS-T</org_study_id>
    <nct_id>NCT02890147</nct_id>
  </id_info>
  <brief_title>Molecular Reclassification to Find Clinically Useful Biomarkers for Systemic Autoimmune Diseases: Case-control</brief_title>
  <acronym>PRECISESADST</acronym>
  <official_title>Molecular Reclassification to Find Clinically Useful Biomarkers for Systemic Autoimmune Diseases: Case-control</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fundación Pública Andaluza Progreso y Salud</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>UCB Biopharma S.P.R.L.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Atrys Health, SA.</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Agencia Estatal Consejo Superior de Investigaciones Científicas</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Servicio Cántabro de Salud</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>August Pi Sunyer Biomedical Research Institute</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Karolinska Institutet</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Katholieke Universiteit Leuven</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Klinikum der Universität Köln</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Hannover Medical School</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Medizinische Universitat Wien</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Quartz Bio S.A.</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Andaluz Health Service</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>The Cyprus Foundation for Muscular Dystrophy Research</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Universidad de Granada</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Milan</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Université Catholique de Louvain</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University Hospital, Brest</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Geneva, Switzerland</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Szeged University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Bayer</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Institut de Recherches Internationales Servier</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Sanofi-Aventis Research &amp; Développement</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Eli Lilly and Company</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Charite University, Berlin, Germany</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Centro Hospitalar do Porto</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Investigación Biomédica de Bellvitge</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Innovative Medicines Initiative</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Andalusian Initiative for Advanced Therapies - Fundación Pública Andaluza Progreso y Salud</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Connective tissue diseases (CTD) or systemic autoimmune diseases (SADs) as they are known
      today are a group of chronic inflammatory conditions with autoimmune aetiology with few
      treatment options and difficult diagnosis.Brest team contribute to perform a new
      classification of the following systemic autoimmune diseases in a European Union's Seventh
      Framework Programme. The aim of this research is to constitute a Healthy Volunteers cohort to
      compare with systemic autoimmune diseases cohort into molecular clusters instead of clinical
      entities through the determination of molecular profiles using several &quot;Omics&quot; techniques.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The main objective of the PRECISESADS project is to reclassify the individuals affected by
      SADs into molecular clusters instead of clinical entities through the determination of
      molecular profiles using several &quot;-omics&quot; techniques.

      The specific objectives of this cross sectional study and sub-study are:

        1. To identify a systemic taxonomy for patients with SADs by producing the following data
           in individuals with SADs and controls: genetic, epigenomic, transcriptomic, flow
           cytometric (from peripheral blood mononuclear and polymorphonuclear cells (PBMCs)),
           metabolomics and proteomic in plasma and urine, exosome analysis, classical serology
           (antibodies and autoantibodies), and clinical data.

        2. To better characterize individual SADs at the omics level.

        3. To perform clustering analyses to determine the groups of individuals who,
           differentially from other groups, share specific molecular features (precision
           medicine).

        4. To identify gene expression, methylation profiles through deconvolution methods
           comparing a mixture of cells with subpopulations determined by flow cytometry with
           separated cells, cytokine profiles and plasma metabolomics using Mass Spectrometry, in a
           substudy of 288 individuals.

      The clustering process will be data-driven with the aim to find the most homogenous and
      differentiated clusters of diseases that clearly separate individuals on the basis of,
      serological, genetic, epigenomic, cellular (cell proportions), metabolomic, proteomic
      (cytokines, autoantibodies) and transcriptome characteristics and differentiate them from
      controls and other patient clusters.

      A total of 2000 patients and 666 controls will be included in the study.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">December 2014</start_date>
  <completion_date type="Actual">October 2017</completion_date>
  <primary_completion_date type="Actual">October 2017</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Gene expression in total blood</measure>
    <time_frame>2 years</time_frame>
    <description>Gene expression will be done using commercial gene expression microarrays in total blood from all samples using the RNA Paxgene tube.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Flow cytometry analysis to determine cell proportions in the total blood mixture in all individuals.</measure>
    <time_frame>24 hours</time_frame>
    <description>9 optimized panels of antibodies will be used to determine cell subpopulations in peripheral blood (including very minor cell populations).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Genotyping</measure>
    <time_frame>2 years</time_frame>
    <description>Genotyping will be done using a whole genome array.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Metabolite determination</measure>
    <time_frame>2 years</time_frame>
    <description>Metabolite determination in plasma and urine using Nuclear Magnetic Resonance</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Exosome isolation from plasma and urine</measure>
    <time_frame>2 years</time_frame>
    <description>set up of the methodology for isolating exosomes in these bodily fluids for gene expression analysis</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Cytokine profile determination</measure>
    <time_frame>2 years</time_frame>
    <description>88 different cytokines will be assessed with Luminex</description>
  </primary_outcome>
  <primary_outcome>
    <measure>routine autoantibodies in serum</measure>
    <time_frame>2 years</time_frame>
    <description>set of serum autoantibodies will be determined in a European validated laboratory. Also, they will perform detection of antibodies against small lipid moieties i.e.antiphosphorylcholine), lupus anticoagulant and complement proteins in plasma.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Gene expression methylation in total blood</measure>
    <time_frame>2 years</time_frame>
    <description>Methylation analysis will be done using the methylome 450k array using the DNA obtained from total blood. MicroRNA gene expression arrays using total blood.</description>
  </primary_outcome>
  <enrollment type="Actual">649</enrollment>
  <condition>Healthy Subjects</condition>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Blood and urine
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Healthy Volunteers
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Aged 18 years or older at the time of consent

          -  Signed the informed consent form

        Exclusion Criteria:

          -  Individuals on chronic medication.

          -  Individuals suffering from any inflammatory, autoimmune, allergic or infectious
             condition and if possible without a history of autoimmune disease, particularly
             thyroid disease or other diseases that may modify cellular profiles in blood.

          -  Pregnant women.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Marta Alarcon</last_name>
    <role>Study Director</role>
    <affiliation>Fundación Pública Andaluza Progreso y Salud (PHFSpain)</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Medical University of Vienna</name>
      <address>
        <city>Vienna</city>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UZ Leuven - KU Leuven, Department of Rheumatology (KU LEUVEN)</name>
      <address>
        <city>Leuven</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHRU de Brest</name>
      <address>
        <city>Brest</city>
        <zip>29609</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Deutsches Rheuma-Forschungszentrum Berlin (DRFZ)</name>
      <address>
        <city>Berlin</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medizinische Hochschule Hannover</name>
      <address>
        <city>Hannover</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Szeged</name>
      <address>
        <city>Szeged</city>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fondazione IRCCS Ca Granda Ospedale Maggiore Policlinico (IRCCS)</name>
      <address>
        <city>Milan</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UNIMI, Istituto Ortopedico Getano Pini</name>
      <address>
        <city>Milan</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centro Hospitalar do Porto</name>
      <address>
        <city>Porto</city>
        <country>Portugal</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Clinic I Provicia- Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS)</name>
      <address>
        <city>Barcelona</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Reina Sofía Andaluz de Salud</name>
      <address>
        <city>Cordoba</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Biobanco del Sistema Sanitario Público de Andalucía (SSPA)</name>
      <address>
        <city>Granada</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario San Cecilio Servicio Andaluz de Salud</name>
      <address>
        <city>Granada</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Virgen de las Nieves Granada</name>
      <address>
        <city>Granada</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Regional de Málaga Servicio Andaluz de Salud</name>
      <address>
        <city>Malaga</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Marqués de Valdecilla, Servicio Cántabro de Salud</name>
      <address>
        <city>Santander</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospitaux Universitaires de Géneve</name>
      <address>
        <city>Geneve</city>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Austria</country>
    <country>Belgium</country>
    <country>France</country>
    <country>Germany</country>
    <country>Hungary</country>
    <country>Italy</country>
    <country>Portugal</country>
    <country>Spain</country>
    <country>Switzerland</country>
  </location_countries>
  <verification_date>April 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 22, 2016</study_first_submitted>
  <study_first_submitted_qc>August 31, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 7, 2016</study_first_posted>
  <last_update_submitted>May 22, 2018</last_update_submitted>
  <last_update_submitted_qc>May 22, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 23, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>SADs</keyword>
  <keyword>Healthy Volunteers</keyword>
  <keyword>Molecular profiles</keyword>
  <keyword>Omics Techniques</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Autoimmune Diseases</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

